The kras mutational spectra of chemically induced lung tumors in different inbred mice mimics the spectra of kras mutations in adenocarcinomas in smokers versus nonsmokers

Journal of Thoracic Oncology

Volumn 5, Issue 2, 2010, Pages 254-257

  Fritz, Jason M ^a   Dwyer Nield, Lori D ^a   Russell, Bridgette M ^a   Malkinson, Alvin M ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

Genetic background determines mutations; Kras mutations in lung cancer; Mouse models of human adenocarcinoma; Smokers and nonsmokers; Strain susceptibilities to Kras mutations

Indexed keywords

3 METHYLCHOLANTHRENE; BUTYLCRESOL; K RAS PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BAGG ALBINO MOUSE; CHRONIC INFLAMMATION; CIGARETTE SMOKING; CODON; COMPARATIVE STUDY; DISEASE COURSE; DNA ISOLATION; EXPERIMENTAL MODEL; GENE MUTATION; HUMAN; INBRED STRAIN; LUNG ADENOCARCINOMA; LUNG TUMOR; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; SEQUENCE ANALYSIS;

EID: 77649115037     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181c8ce04     Document Type: Article

References (19)

1. Sun S, Schiller JH, Gazdar AF, et al. Lung cancer in never smokers-a different disease. Nat Rev Cancer 2007;7:778-790.
2. Riely GJ, Kris MG, Rosenbaum D, et al. Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. Clin Cancer Res 2008;14:5731-5734.
3. Downward J. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 2003;3:11-22.
4. Malkinson AM. Primary lung tumors in mice as an aid for understanding, preventing, and treating human adenocarcinoma of the lung. Lung Cancer 2001;32:265-279.
5. You M, Candrian U, Maronpot RR, et al. Activation of the Ki-ras protooncogene in spontaneously occurring and chemically induced lung tumors of the strain A mouse. Proc Natl Acad Sci USA 1989;86:3070-3074.
6. Bauer AK, Dwyer-Nield LD, Keil K, et al. Butylated hydroxytoluene (BHT) induction of pulmonary inflammation: a role in tumor promotion. Exp Lung Res 2001;27:197-216.
7. Dwyer-Nield LD, McQuillian J, Hill-Baskin A, et al. Epistatic interactions govern chemically-induced lung tumor susceptibility and Kras mutation site in murine C57BL/6J-ChrA/J chromosome substitution strains. Int J Cancer. 2010;126:125-132.
8. Zerbe LK, Dwyer-Nield LD, Fritz JM, et al. Inhibition by erlotinib of primary lung adenocarcinoma at an early stage in male mice. Cancer Chemother Pharmacol 2008;62:605-620.
9. Lin L, Festing MF, Devereux TR, et al. Additional evidence that the K-ras protooncogene is a candidate for the major mouse pulmonary adenoma susceptibility (Pas-1) gene. Exp Lung Res 1998;24:481-497.
10. Sithanandam G, Ramakrishna G, Diwan BA, et al. Selective mutation of K-ras by N-ethylnitrosourea shifts from codon 12 to codon 61 during fetal mouse lung maturation. Oncogene 1998;17:493-502.
11. Forbes SA, Bhamra G, Bamford S, et al. The Catalogue of Somatic Mutations in Cancer (COSMIC). Curr Protoc Hum Genet 2008;Chapter 10:unit 10.11 (database online). Available at: http://www.sanger.ac.uk/ genetics/CGP/cosmic. Accessed September 9, 2009.
12. Gealy R, Zhang L, Siegfried JM, et al. Comparison of mutations in the p53 and K-ras genes in lung carcinomas from smoking and nonsmoking women. Cancer Epidemiol Biomarkers Prev 1999;8:297-302.
13. Wu CC, Hsu HY, Liu HP, et al. Reversed mutation rates of KRAS and EGFR genes in adenocarcinoma of the lung in Taiwan and their implications. Cancer 2008;113:3199-3208.
14. Nikitin AY, Alcaraz A, Anver MR, et al. Classifcation of proliferative pulmonary lesions of the mouse: recommendations of the mouse models of human cancers consortium. Cancer Res 2004;64:2307-2316.
15. Gressani KM, Leone-Kabler S, O'Sullivan MG, et al. Strain-dependent lung tumor formation in mice transplacentally exposed to 3-methylcholanthrene and post-natally exposed to butylated hydroxytoluene. Carcinogenesis 1999;20:2159-2165.
16. Lu LJ, Harvey RG, Lee H, et al. Age-, tissue-, and Ah genotypedependent differences in the binding of 3-methylcholanthrene and its metabolite(s) to mouse DNA. Cancer Res 1990;50:4239-4247.
17. Recktenwald CV, Kellner R, Lichtenfels R, et al. Altered detoxification status and increased resistance to oxidative stress by K-ras transformation. Cancer Res 2008;68:10086-10093.
18. Kohno T, Kunitoh H, Suzuki K, et al. Association of KRAS polymorphisms with risk for lung adenocarcinoma accompanied by atypical adenomatous hyperplasias. Carcinogenesis 2008;29:957-963.
19. Nemunaitis J, Murray N. Immune-modulating vaccines in non-small cell lung cancer. J Thorac Oncol 2006;1:756-761.